Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating margin is N/A as of Tuesday, October 6, 2026.
OPERATING MARGIN
N/A
Market Cap
$562.76M
Operating Margin
-29.35%
TTM Avg
-5.63%
3Y Avg
-52.07%
5Y Avg
-106.16%
Market Cap
$566.43M
Operating Margin
46.95%
TTM Avg
-1.63%
3Y Avg
-11705.79%
5Y Avg
-12269.85%
Market Cap
$548.18M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$548.84M
Operating Margin
-975.91%
TTM Avg
-867.04%
3Y Avg
-586.91%
5Y Avg
-743.36%
Market Cap
$546.55M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$572.76M
Operating Margin
-156.36%
TTM Avg
-104.91%
3Y Avg
-81.98%
5Y Avg
-81.61%
Market Cap
$539.25M
Operating Margin
-91.36%
TTM Avg
-296.77%
3Y Avg
-6281.52%
5Y Avg
-4187.68%
Market Cap
$538.54M
Operating Margin
-1.90%
TTM Avg
-16.29%
3Y Avg
-781.66%
5Y Avg
-851.82%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $562.76M | -29.35% | -5.63% | -52.07% | -106.16% |
| CorMedix Inc. (CRMD)vs › | $566.43M | 46.95% | -1.63% | -11705.79% | -12269.85% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $548.18M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $548.84M | -975.91% | -867.04% | -586.91% | -743.36% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $546.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $572.76M | -156.36% | -104.91% | -81.98% | -81.61% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $539.25M | -91.36% | -296.77% | -6281.52% | -4187.68% |
| Delcath Systems, Inc. (DCTH)vs › | $538.54M | -1.90% | -16.29% | -781.66% | -851.82% |
| ProKidney Corp. (PROK)vs › | $532.96M | -18477.83% | -130078.39% | -65039.20% | -43359.46% |
Gross Margin
N/A
Operating Margin
N/A
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
